Morgan Stanley analyst Ravi Shanker maintains Hub Group (NASDAQ:HUBG) with a Equal-Weight and raises the price target from $86 to $87.
Why Is Genetic Disease-Focused Alnylam Pharmaceuticals Stock Trading Lower Today?
The FDA has issued a Complete Response Letter (CRL) to Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) supplemental New Drug Application (sNDA) for patisiran for cardiomyopathy of transthyretin-